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INTENTIONAL INDUCTION OF MIXED HEMATOPOIETIC CHIMERISM AS
PLATFORM FOR CELLULAR THERAPY AFTER HLA-MATCHED ALLOGE-
NEIC STEM CELL TRANSPLANTATION IN CHILDHOOD LEUKEMIA PA-
TIENTS
Perez, A.1, Gonzalez, M.1, Ramirez, M.1, Sevilla, J.1, Diaz, M.A.1
1Hospital “Nin˜o Jesus”, Madrid, Spain.
To maximize graft-versus-leukemia (GvL) effect while minimiz-
ing or avoiding graft-versus-host disease (GvHD) we designed a
prospective study of allogeneic PBSC transplantation aimed to
achieve a mixed chimerism (MC) status. In order to ensure this
objective we combined the use of reduced-intensity conditioning
and graft manipulation by means of CD34 selection. To improve
immunological reconstitution early “low dose” (0.5  105/Kg
CD3 cells) DLI was scheduled once a month for six months. The
PBSC CD34 selection was performed by CliniMACS device.
Between June 2004 and June 2006, twenty two consecutive patients
(8 females and 14 males) aged between 1-16 years (median 6 years)
diagnosed of AML 9, ALL 13 were conditioned with ﬂudarabine
30 mg/m2/day x 5 days plus melphalan 140 mg/m2/day x 1 day
(n19) or plus busulphan 3.2 mg/kg/day x 2 days (n2). Status at
transplantation was 1st CR 14, 2nd CR 7 and 3th CR 1. GvHD
prophylaxis consisted of CsA  short Mtx. Patients were grafted
with a median number of 6  106/Kg CD34 cells (range: 2-31 
106/Kg) and 1.1  104 CD3 cells (range: 0.2-3.9  104/Kg). All
patients engrafted and MC was detected in all. Median time to
neutrophil and platelet engraftment was 13 days (range: 9-16 days)
and 13 days (range: 8-24 days), respectively. A total of 65 DLI were
performed. One patient had acute GvHD grade I after 2nd DLI
that resolved with topical steroid treatment and another one de-
veloped graft hypoplasia after ﬁrst DLI resolved after G-CSF
treatment. One patient died due to engraftment syndrome. No
patients developed GvHD  grade II. The Kaplan-Meier proba-
bility of relapse was 229%. With a median follow-up of 15
months (range: 3-24 months) the probability of disease-free sur-
vival was 789%. The secondary graft failure probability was
205%. Risk factors for secondary graft failure were sex-mismatch
(female recipient-male donor) and transplantation from unrelated
donors. The main cause of death was relapsing disease. No severe
viral and fungal infections were observed. These preliminary re-
sults suggest that the intentional induction of MC avoids serious
GvHD but it is not associated with an increase risk of relapsing
disease. However, secondary graft failure is an emerging problem
especially in the unrelated transplantation setting.
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CHRONIC GVHD DECREASES ANTI-CMV IMMUNE RESPONSES IN ALLO-
GENEIC BMT: DEFECT IN T-CELL HOMING
Hossain, M.S.1, Roback, J.D.2, Pollack, B.P.3, Jaye, D.L.2,
Waller, E.K.1 1Department of Hematology and Oncology, Emory Uni-
versity, Atlanta, GA; 2Department of Pathology and Laboratory Medi-
cine, Emory University, Atlanta, GA; 3Department of Dermatology and
Pathology, Emory University, Atlanta, GA.
Backgound: The major complications of allogeneic bone marrow
transplantation are relapse, acute and chronic Graft-vs-Host Dis-
ease (aGvHD; cGvHD) and opportunistic infections, especially
cytomegalovirus (CMV). In this study, we investigated the effect of
cGvHD on susceptibility to murine CMV infection following
allogeneic BMT, focusing on the contribution of cGvHD to func-
tional immunodeﬁciency.
Method: We used a parent to F1 model of allogeneic BMT to
test the hypothesis that cGvHD leads to impaired anti-viral im-
munity. Irradiated CB6F1 recipients of 3106 untreated donor
splenocytes developed non-lethal cGvHD compared to control
mice without GvHD that had received TCD bone marrow alone
or BM plus amotosalen (a water soluble synthetic S-59 psoralen
compound) -treated splenocytes10106. Mice were challenged
with a non-lethal dose of murine CMV 100 days post transplant.
Flow cytometry was used to quantitate T cells isolated from the
recipient organs. Liver viral load was determined by counting PFU
in tissue homogenates plated onto 3T3 conﬂuent monolayers.
Assessment of cGvHD was done by monitoring weight loss and
scored through histological analysis of tissue sections.
Results: Recipients with cGvHD had more weight loss and
higher viral loads in the spleen and liver. Murine CMV infection
led to 130- and 30 -fold expansion of donor spleen-derived T-cells
in the blood of transplant recipients with and without chronic
GvHD, respectively, as well as marked expansion of CMV-pep-
tide-speciﬁc-tetramer CD8 T-cells. Mice with chronic GvHD
had lymphopenia in secondary lymphoid organs and severe depres-
sion of the numbers of antigen-speciﬁc anti-viral T-cells in the
spleen and liver compared to control mice.
Conclusion: Functional immunodeﬁciency in mice with cGvHD
and MCMV infection are consistent with the clinical reports that
document an increased incidence of opportunistic viral infections
in patients with cGvHD. Expansion of donor T cells in blood
occurred against viral infection but these T-cells failed to mount
effective anti-viral immune responses in the spleen and liver. In
contrast transplant recipients of amotosalen-treated splenocytes
successfully developed brisk and effective anti-viral immune re-
sponses. These ﬁndings provide an opportunity to design a novel
approaches for the treatment of cancer patients undergoing allo-
geneic BMT that may reduce the incidence of cGvHD, organ
speciﬁc immunodeﬁciency and opportunistic infections.
Table 1. T cells in the blood and liver of recipients with cGvHD, and
no GvHD after day 10 MCMV infection1.
Blood Liver
cGvHD
No GVHD
cGvHD cGvHD
No GVHD
cGvHD
T cell number2
Donor spleen 130 31.0 3.8 2.49
Donor BM 7.1 11.1 3.2
Host 15.0 6.8 2.7 1.8
Absolute numbers of
MCMV specific
tetramer CD8
T cells per tissue3
Donor spleen 38.6  33.1 9.3  5.5 50.1  38.6 178  124.9*
Donor BM 13.6  8.5* 32.1  9.2* 65.2  45.8 226.3  99.2*
Host 6.2  6.2 11.3  4.5* 17.9  6.1 14.2  11.1
1Recipients of untreated splenocytes (cGvHD) and amotosalen-
treated (no GvHD) were bled on 133 days post transplant (day
0), and bled on day 10 after 5104 PFU MCMV i.p. infection.
Liver lymphocytes were isolated on day 0 after MCMV infec-
tion (day100 post transplant) and day 10 after post infection.
2The fold-expansion data were calculated by dividing number of
T-cells per ml of blood and per liver on day 10 postinfection
with the baseline number of T-cells present on day 0 of infec-
tion.
3The absolute number of MCMV peptide speciﬁc tetramer
CD8 T cells (x103)T cells per mL of blood and per liver were
determined by FACS analysis on day 10 after MCMV infec-
tion. *p0.05(Student t-test) compared with the cGvHD. 4 to
5 mice were used per group.
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HIGHER-ORDER CYTOKINE FLOW CYTOMETRY REVEALS DISTINCT
FUNCTIONAL SIGNATURES OF MATURATION SUBSETS OF CD4 AND
CD8 T CELLS
Kim, T.K.1, St. John, L.S.1, Wieder, E.D.1, Molldrem, J.J.1,
Komanduri, K.V.1 1Dept. of Stem Cell Transplantation & Cellular
Therapy, MD Anderson Cancer Center, Houston, TX; University of
Houston, Houston, TX; University of Houston, Houston, TX; Fleury-
Diagnostic Medical Center, Sao Paolo, TX.
Our clinical studies have suggested that impaired immune recov-
ery after SCT is associated with greater proportions of circulating
memory and late memory cells, as deﬁned by phenotyping. To
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